多潘立酮联合伊托必利治疗功能性消化不良的临床疗效和安全性探讨

摘要

Objective: To investigate the clinical efifcacy and safety of domperidone combined with itopride in the treatment of functional dyspepsia.Methods:The patients with functional dyspepsia were divided into an observation group (63 cases, treated with domperidone and itopride) and a control group (60 cases, treated with domperidone only). The dyspepsia symptoms such as anorexia, epigastric pain and postprandial discomfort and the clinical efifcacy were compared between two groups before and after the treatment.Results:The efifciency in the observation group (92.06%) was signiifcantly higher than that in the control group (58.33%). After the treatment, the total symptom integral and the clinical symptoms in all patients were signiifcantly improved (P<0.05).Total symptom score and the clinical symptom scores in epigastric pain, postprandial discomfort, loss of appetite and so on were signiifcantly lower in the observation group than in the control group (P<0.05). The comparison of the adverse reactions of drugs between two groups had no signiifcant difference (P<0.05). Conclusion:Domperidone combined with itopride has better clinical efifcacy and higher safety in the treatment of functional dyspepsia, which is worthy of clinical use.%目的：探讨多潘立酮联合伊托必利治疗功能性消化不良的临床疗效和安全性。方法：服用多潘立酮联合伊托必利治疗的63例功能性消化不良患者为观察组，服用多潘立酮治疗的60例功能性消化不良患者为对照组，比较两组患者治疗前后食欲不振、上腹痛、餐后不适等消化不良症状情况和临床疗效。结果：观察组治疗有效率为92.06%，显著高于对照组（58.33%）；经治疗后，全部患者总症状积分和临床症状均明显改善（P＜0.05），观察组总症状积分和上腹痛、餐后不适、食欲不振等临床症状的评分均明显低于对照组（P＜0.05）；两组药物不良反应比较差异无显著性（P＞0.05）。结论：多潘立酮联合伊托必利治疗功能性消化不良的临床疗效更佳，安全性高，值得临床推广使用。